Appendix
← Clinical Reader
Ophthalmology

Bimatoprost Ophthalmic Solution

Bimatoprost ophthalmic solution is a medication that addresses medical and cosmetic concerns. This activity discusses this eye drop's chemical intricacies, pharmacodynamics, and pharmacokinetics, shedding light on its therapeutic role in reducing intraocular pressure (IOP) among patients with primary open-angle glaucoma (POAG) and ocular hypertension. This prostaglandin (PG) F2 alpha analog exerts its influence by activating bimatoprost-sensitive receptors scattered across various ocular structu

v1 · Reviewed Nov 7, 2026 by Automated Clinical Reviewer (Strict Verbatim v1)
  • Bimatoprost may not be appropriate for some cases of closed-angle glaucoma and inflammatory or neovascular glaucoma.
  • Intraocular application of bimatoprost ophthalmic solution for glaucoma is contraindicated in neonates, infants, and children due to concern for pigmentation changes after long-term use.
  • Bimatoprost is considered a category-C drug for pregnancy.
  • The effects in reducing IOP begin about 4 hours after the topical instillation of bimatoprost, which reaches maximum effects after 8 to 12 hours and lasts for 24 hours
  • Numerous studies have confirmed that IOP reduction ranges from 28% to 31% with prostaglandins.
  • The majority of the studies regarding bimatoprost have shown clinical efficiency and first-line therapy in reducing IOP in patients with primary open-angle glaucoma (POAG) and ocular hypertension (OHT).
  • Ophthalmic topical bimatoprost is a synthetic prostamide structurally related to prostaglandin F2 alpha (F2α).
  • This drug received approval from the United States Food and Drug Administration (FDA) in 2001 as a treatment to lower intraocular pressure (IOP).
  • Evidence indicates that topical bimatoprost reduces IOP in eyes with primary open-angle glaucoma (POAG) and ocular hypertension.
  • In 2008, the FDA-approved ophthalmic bimatoprost to treat hypotrichosis, such as for patients who are post-chemotherapy.
  • It has been well demonstrated and validated that bimatoprost and several topical prostaglandin analogs sustainably and effectively reduce interaocular pressure (IOP) and are used as a standard first-line treatment of POAG.
  • This prostaglandin reduces IOP and is considered one of the most efficient antiglaucomatous topical and first-line therapies compared to other monotherapy drop alternatives.
bimatoprost ophthalmic solution
topical
Adult
1 drop every evening
Renal
Not specified in source
Duration
Not specified in source
bimatoprost ophthalmic solution
topical
Adult
once-daily dosing
Renal
Not specified in source
Duration
Not specified in source
bimatoprost ophthalmic solution 0.03%
applied to the upper eyelashes
Adult
Once-daily
Renal
Not specified in source
Duration
Not specified in source
  • Contact lenses should be removed before the bimatoprost ophthalmic solution is applied.
  • They can be reinserted after 15 minutes.
  • The safety and efficacy of bimatoprost ophthalmic 0.03% dermal application for hypotrichosis have not been studied in children, neonates, and infants younger than 5 years old.
  • Bimatoprost ophthalmic solution has not been adequately studied in pregnant women and pediatric patients; it should be avoided or used cautiously in these cases unless deemed necessary.
  • The presence or absence of the drug in breast milk has not been established, considering the short half-life; it should be avoided during nursing if possible.
  • Pressure can be placed over the tear duct for about a minute, and removal of excess therapy with a tissue can be considered after applying ocular drops to decrease the amount of drug in the bloodstream.
  • Bimatoprost ophthalmic drops should be used with caution in patients with macular edema, uveitis, ocular inflammation, aphakia, complicated pseudophakia, a history of herpes simplex virus keratitis, and ocular inflammatory conditions.
  • Carbonic anhydrase inhibitors have shown to be a valid alternative to bimatoprost during the early pre and postoperative periods or in patients with inflammation at risk of CME.
  • To treat glaucoma and ocular hypertension, bimatoprost ophthalmic solution should be initially monitored with regular clinic visits every 2 to 4 weeks until the patient's individualized target IOP is achieved.
  • After reaching the IOP goal, the patient can be reassessed every 6 months or at the clinician's discretion.
  • Additional parameters to monitor include ocular peri-ocular pigmentation changes.
  • When using bimatoprost ophthalmic solution 0.03% dermally for hypotrichosis, monitoring for potential side effects is advised.
  • When bimatoprost is discontinued, eyelashes may return to their original pre-treatment length and thickness.
  • Currently, no studies have been performed to evaluate bimatoprost overdose in humans.
  • If an overdose were to occur, manufacturers recommend supportive symptomatic treatment.
  • review
    Bimatoprost Ophthalmic Solution. StatPearls [Internet] — Andy S. Huang, Marco Zeppieri, Jay J. Meyer — StatPearls Publishing, 2024

Decision support only. Verify against local protocols and current labeling. Source: www.ncbi.nlm.nih.gov